New APE1 Redox Inhibitor Molecule (E3330)

Littleton, CO, April 07, 2011 --( AP Endonuclease 1 (APE1), also known as REF-1, is an enzyme primarily responsible for DNA base excision repair. In addition to a DNA repair domain, APE-1 also contains a redox regulation domain to help activate other enzymes involved in the DNA repair pathway. APE 1 is found overexpressed in many human cancers and is required for cancer cell viability, making APE-1 inhibition a potentially important target for cancer therapy.

E3330, a small-molecule inhibitor of APE 1 redox domain function, has been used to significantly reduce the growth of human pancreatic cancer cells in vitro [PMID: 18645011]. Therefore, E3330 is expected to emerge as a useful tool for treatment of certain cancers.

Novus Biologicals is excited to announce the commercial release of this E3330 APE1 redox inhibitor (catalog number NBP1-49581). This product may be used to inhibit APE1redox activity in vivo for studies on cancer cell stability and proliferation. Novus also offers a complete line of APE1 products for use with the E3330 inhibitor. All Novus products are 100% guaranteed to work in the species and applications listed on the datasheet, and the Innovator's Reward Program supports testing in novel species and applications.

About Novus Biologicals (
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.

Novus Biologicals
Amy Chamberlain-Torres